查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933294

全球皮癣菌甲癣治疗市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的考虑因素以及未来预测（2026-2034 年）

Dermatophytic Onychomycosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 136 Pages | 商品交期: 请询问到货日

价格

皮癣菌甲癣治疗市场成长因素

2025 年，全球皮癣菌甲癣治疗市场规模为 57.4 亿美元。预计该市场将从 2026 年的 61.7 亿美元成长至 2034 年的 109.9 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 7.49%。

北美地区在 2025 年占市场主导地位，市占率达 44.33%，这主要得益于高处方量、强有力的报销政策以及品牌外用药物的广泛应用。

皮癣菌性甲癣 (ONY) 是一种主要由皮癣菌引起的指甲真菌感染，约占全球所有甲癣病例的 70-80%。此病会导致指甲变色、增厚和脆弱，严重影响患者的生活品质。糖尿病盛行率上升、人口老化以及人们对甲癣认识的提高是推动有效治疗需求的关键因素。

市场概览

甲癣约占全球指甲疾病的 50%，全球人口盛行率估计为 5.5%。老年人和糖尿病患者的盛行率更高，因此对局部和口服抗真菌药物的需求长期存在。由于诊断率的提高、皮肤科医疗服务的可近性改善以及处方药和非处方药的广泛普及，市场持续稳定成长。

由于病患就诊量减少和诊断延迟，COVID-19 疫情暂时影响了市场。然而，诊所的重新开放、远距皮肤科咨询的日益普及以及患者意识的提高，正在推动疫情后的復苏。

市场动态

市场驱动因素

皮癣菌性甲癣盛行率的上升仍然是市场成长的主要驱动因素。据 Moberg Pharma AB 称，全球约有 10% 的人口患有甲癣，光是美国就有 3,500 万至 4,000 万例。此外，糖尿病盛行率的上升也显着增加了真菌性甲癣的易感性。

另一个关键驱动因素是对更安全的治疗方案的需求不断增长。 口服抗真菌药物与肝毒性有关，因此医生通常会开立外用指甲油，尤其是在治疗轻度至中度感染时。

市场限制因子

认知度低和治疗依从性差仍然是主要挑战。研究表明，口服治疗的依从率仅为 45%，而外用治疗的依从率仅为 24%，这主要是由于治疗週期长和患者教育不足。这些因素阻碍了及时诊断和有效治疗，减缓了整体市场成长。

市场趋势

转向外用治疗

市场的关键趋势是逐渐转向外用解决方案，包括含药指甲油。由于全身副作用减少和安全性提高，Juvria（依芬那唑）和环吡酮胺等产品越来越受欢迎。不断创新以提高药物对甲床的渗透性进一步强化了这一趋势。

依细分市场分析

依产品类型

市场依产品类型细分：片剂和指甲油。

预计到2026年，指甲油细分市场将占主导地位，市占率达50.29%，这主要得益于外用疗法的日益普及以及Jublia的强劲销售。

由于特比萘芬等口服抗真菌仿製药的供应不断增加，预计片剂细分市场将保持稳定成长。

依给药途径

预计到2026年，外用药物将以50.29%的市占率领先。这主要得益于研发投入的增加以及FDA对多种外用抗真菌候选药物的批准。口服疗法虽然有效，但有安全隐患。

依通路划分

预计2026年，零售药局将占市场主导地位，市占率达40.62%。这主要得益于非处方药的高销售量和不断扩张的药局网路。由于疫情后人们购买便利性增加以及行为习惯的改变，预计线上药局也将实现强劲成长。

区域因素

预计到2025年，北美市场规模将达到25.4亿美元，主要得益于处方量高和对品牌药的强劲需求。

在有利的报销政策和仿製药使用量不断增加的推动下，欧洲的甲癣盛行率为4.3%。

预计亚太地区将以最高的复合年增长率成长，这主要得益于糖尿病盛行率的上升、人口老龄化以及日本、中国和印度新产品的上市。

销售单位：1,000 单位

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 流行病学：主要国家和地区的皮癣菌性甲癣（2025 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等等。
  • COVID-19 对市场的影响

第五章 全球皮癣菌甲癣治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品类型划分
    • 片剂
    • 指甲油
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 外用
  • 市场分析、洞察与预测：依类型划分
    • 处方药
    • 非处方药 (OTC)
  • 市场分析、洞察与预测：依销售管道划分
    • 医院药房
    • 零售药房
    • 线上渠道
  • 市场分析，洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区 (ROW)

第六章 北美皮癣菌甲癣治疗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲皮癣菌甲癣治疗市场分析：洞察与预测 (2021-2034)

第八章 亚太地区皮癣菌甲癣治疗市场分析：洞察与预测 (2021-2034)

章节9.世界其他地区（ROW）皮癣菌甲癣治疗市场分析：洞察与预测（2021-2034）

第十章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Galderma
    • Cipla Inc.
    • Janssen Pharmaceuticals, Inc.
    • Kaken Pharmaceuticals Co., Ltd.
Product Code: FBI103310

Growth Factors of dermatophytic onychomycosis treatment Market

The global dermatophytic onychomycosis treatment market was valued at USD 5.74 billion in 2025. The market is projected to grow from USD 6.17 billion in 2026 to USD 10.99 billion by 2034, exhibiting a CAGR of 7.49% during the forecast period (2026-2034).

North America dominated the market in 2025 with a 44.33% share, supported by a high number of prescriptions, strong reimbursement policies, and widespread adoption of branded topical therapies.

Dermatophytic onychomycosis is a fungal nail infection caused primarily by dermatophytes, accounting for nearly 70%-80% of onychomycosis cases globally. The disease leads to nail discoloration, thickening, and brittleness, significantly impacting patient quality of life. Rising prevalence of diabetes, aging populations, and increasing awareness of nail fungal infections are major contributors to the expanding demand for effective treatment options.

MARKET OVERVIEW

Onychomycosis represents nearly 50% of all nail disorders worldwide, with an estimated 5.5% global population prevalence. The condition is more common in elderly individuals and diabetic patients, creating long-term demand for both topical and oral antifungal therapies. The market is witnessing steady growth due to increased diagnosis rates, improved access to dermatology services, and availability of both prescription and OTC treatment options.

The COVID-19 pandemic temporarily impacted the market due to reduced patient visits and delayed diagnosis. However, post-pandemic recovery has been supported by clinic reopenings, growing teledermatology adoption, and increased patient awareness.

MARKET DYNAMICS

Market Drivers

The rising prevalence of dermatophytic onychomycosis remains the primary driver of market growth. According to Moberg Pharma AB, nearly 10% of the global population suffers from onychomycosis, with 35-40 million cases in the U.S. alone. Additionally, the growing diabetic population significantly increases susceptibility to fungal nail infections.

Another key driver is the increasing demand for safer treatment alternatives. Oral antifungal drugs are associated with liver toxicity, leading physicians to favor topical nail lacquers, particularly for mild-to-moderate infections.

Market Restraints

Lack of awareness and poor treatment adherence are major challenges. Studies indicate adherence rates of only 45% for oral therapies and 24% for topical treatments, largely due to long treatment durations and limited patient education. These factors restrict timely diagnosis and effective treatment, slowing overall market growth.

MARKET TRENDS

Shift Toward Topical Therapies

A major trend in the market is the gradual shift toward topical solutions, including medicated nail paints and lacquers. Products such as Jublia (efinaconazole) and ciclopirox are increasingly preferred due to lower systemic side effects and improved safety profiles. Continuous innovation aimed at enhancing nail bed penetration is further strengthening this trend.

SEGMENTATION ANALYSIS

By Product Type

The market is segmented into tablets and nail paints.

The nail paints segment dominated the market in 2026, accounting for 50.29% market share, driven by rising adoption of topical therapies and strong sales of Jublia.

The tablets segment is expected to grow steadily due to increasing availability of generic oral antifungals such as terbinafine.

By Route of Administration

The topical segment led the market in 2026 with a 50.29% share, supported by increasing R&D investments and FDA approvals for topical antifungal candidates. Oral therapies remain effective but are limited by safety concerns.

By Distribution Channel

Retail pharmacies dominated the market in 2026 with a 40.62% share, owing to high OTC drug sales and expanding pharmacy networks. Online pharmacies are expected to witness strong growth due to convenience and post-pandemic behavioral shifts.

REGIONAL INSIGHTS

North America generated USD 2.54 billion in 2025, driven by high prescription volumes and strong demand for branded products.

Europe is supported by favorable reimbursement policies and increasing use of generics, with onychomycosis prevalence at 4.3%.

Asia Pacific is expected to grow at the fastest CAGR due to rising diabetes prevalence, aging populations, and new product launches in Japan, China, and India.

COMPETITIVE LANDSCAPE

The market is moderately consolidated, led by Bausch Health Companies Inc., primarily due to strong sales of Jublia. Other prominent players include Pfizer Inc., Galderma, GlaxoSmithKline plc, Cipla Inc., and Kaken Pharmaceuticals Co., Ltd. Strategic initiatives such as generic launches, licensing agreements, and geographic expansion are shaping competitive dynamics.

CONCLUSION

The global dermatophytic onychomycosis treatment market is experiencing consistent growth, driven by rising disease prevalence, increasing diabetic and geriatric populations, and growing preference for safer topical therapies. With the market expanding from USD 5.74 billion in 2025 to USD 10.99 billion by 2034, advancements in drug formulation, expanding OTC availability, and improved patient access are expected to support long-term market expansion. Continued innovation, growing awareness, and favorable regulatory developments are likely to strengthen the adoption of dermatophytic onychomycosis treatments during the forecast period.

CAGR CAGR of 7.49% from 2026-2034

Unit Volume (K Units)

Segmentation By Product Type

  • Tablets
  • Nail Paints

By Route of Administration

  • Oral
  • Topical

By Type

  • Prescribed
  • Over-the-Counter (OTC)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

By Geography

  • North America (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Russia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Southeast Asia
    • Rest of Asia Pacific

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology: Dermatophytic Onychomycosis, Key Countries/ Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions and Partnerships
  • 4.5. Impact of COVID-19 on the Market

5. Global Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Tablets
    • 5.1.2. Nail Paints
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Topical
  • 5.3. Market Analysis, Insights and Forecast - By Type
    • 5.3.1. Prescribed
    • 5.3.2. Over-the-Counter (OTC)
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Channels
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of World

6. North America Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Tablets
    • 6.1.2. Nail Paints
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Topical
  • 6.3. Market Analysis, Insights and Forecast - By Type
    • 6.3.1. Prescribed
    • 6.3.2. Over-the-Counter (OTC)
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Channels
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Tablets
    • 7.1.2. Nail Paints
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Topical
  • 7.3. Market Analysis, Insights and Forecast - By Type
    • 7.3.1. Prescribed
    • 7.3.2. Over-the-Counter (OTC)
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Channels
  • 7.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Russia
    • 7.5.8. Rest of Europe

8. Asia Pacific Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Tablets
    • 8.1.2. Nail Paints
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Topical
  • 8.3. Market Analysis, Insights and Forecast - By Type
    • 8.3.1. Prescribed
    • 8.3.2. Over-the-Counter (OTC)
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Channels
  • 8.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. New Zealand
    • 8.5.6. Southeast Asia
    • 8.5.7. Rest of Asia Pacific

9. Rest of World Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Tablets
    • 9.1.2. Nail Paints
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Topical
  • 9.3. Market Analysis, Insights and Forecast - By Type
    • 9.3.1. Prescribed
    • 9.3.2. Over-the-Counter (OTC)
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Channels

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. GlaxoSmithKline plc
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Pfizer Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Galderma
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Cipla Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Janssen Pharmaceuticals, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Kaken Pharmaceuticals Co., Ltd.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 4: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 6: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 7: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 9: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 12: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 17: Table 19: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 19: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Product, 2021-2034
  • Table 22: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 24: Rest of World Dermatophytic Onychomycosis Treatment Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Dermatophytic Onychomycosis Treatment Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 5: Global Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 7: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 8: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 9: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 12: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 13: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 16: North America Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country, 2025
  • Figure 17: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 18: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 19: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 22: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 23: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 28: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 29: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 32: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 33: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Dermatophytic Onychomycosis Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Product, 2025 & 2034
  • Figure 38: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Product, 2025
  • Figure 39: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Route of Administration, 2025 & 2034
  • Figure 40: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 42: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Type, 2025
  • Figure 43: Rest of World Dermatophytic Onychomycosis Treatment Market Value (USD Billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Rest of World Dermatophytic Onychomycosis Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Global Dermatophytic Onychomycosis Treatment Market Share (%), By Company, 2025